NASDAQ:ALBT Avalon GloboCare 5/30/2024 Earnings Report $2.73 +0.04 (+1.49%) Closing price 04:00 PM EasternExtended Trading$2.70 -0.03 (-1.06%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Avalon GloboCare EPS ResultsActual EPS-$1.80Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAvalon GloboCare Revenue ResultsActual Revenue$0.32 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAvalon GloboCare Announcement DetailsQuarterDate5/30/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsAvalon GloboCare's next earnings date is estimated for Monday, November 10, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Avalon GloboCare Earnings HeadlinesWall Street Zen Downgrades Avalon GloboCare (NASDAQ:ALBT) to Strong SellSeptember 14, 2025 | americanbankingnews.comAvalon GloboCare Corp. Announces Launch of KetoAir™ Breathalyzer Device in the UKAugust 28, 2025 | quiverquant.comQTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real wealth for early adopters In 1933, Executive Order 6102 forced everyday Americans to hand over their gold at a fixed rate. Everyday citizens lost a sizable amount of their hard earned wealth at the stroke of FDR's pen.September 22 at 2:00 AM | American Hartford Gold (Ad)Avalon GloboCare to Launch Online Sales of KetoAir Breathalyzer in the United KingdomAugust 28, 2025 | globenewswire.comALBT Avalon GloboCare Corp. - Seeking AlphaAugust 23, 2025 | seekingalpha.comAvalon GloboCare Issues Unregistered Common StockAugust 13, 2025 | msn.comSee More Avalon GloboCare Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avalon GloboCare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalon GloboCare and other key companies, straight to your email. Email Address About Avalon GloboCareAvalon GloboCare (NASDAQ:ALBT) is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection. Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies. Its technology platforms include exoSTAMP, designed for highly sensitive isolation and analysis of circulating exosomes, and exoSC, aimed at scalable manufacturing of exosome-based products. The company maintains strategic collaborations with academic and clinical partners to accelerate development timelines and broaden the potential application of its technologies. These partnerships support Avalon’s efforts to optimize manufacturing processes, refine product specifications and initiate clinical trials in oncology and, potentially, viral diseases where cell therapy approaches can address unmet medical needs. Founded in 2016 and publicly listed on NASDAQ under the ticker ALBT, Avalon GloboCare is led by Dr. Leem Chao, its Chairman and Chief Executive Officer. Under his leadership, the company has expanded its footprint across key biopharma hubs and continues to advance a diversified portfolio of innovative therapies and diagnostics designed to improve patient outcomes worldwide.View Avalon GloboCare ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Berkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into Believers Upcoming Earnings Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Citigroup (10/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
